Tukysa 50 mg tablet is a prescription medicine containing Tucatinib for oral use, marketed by Seagen, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature at 20ºC to 25ºC (68ºF to 77ºF)…
Key facts
- Active ingredient (INN)
- Tucatinib
- Brand
- Tukysa
- Strength
- 50 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets
- Marketing authorisation holder
- Seagen
- Manufacturer
- Seagen
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted from 15ºC to 30ºC (59ºF to 86ºF). Store in original container to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EH03 Tucatinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 April 2020
- Identifiers
- RxCUI 2361290, 2361296, 2361298 +1DailyMed set ID f27eb1b9-b7fc-424e-988f-84dd7bb195a3NDC 51144-001Application NDA213411
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet in 1 bottle | 51144-001-60 | Seagen | 17 April 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tucatinib
Clinical summary
Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment, among other approved uses. MedsAcross supplies Tucatinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TucatinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TUKYSA prescribing information (Seagen) · U.S. National Library of Medicine, DailyMed
- Tukysa: European public assessment report (EPAR) · European Medicines Agency
Need Tukysa 50 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.